Cadrenal Therapeutics (CVKD) said Tuesday it has signed a collaboration agreement with Abbott (ABT) to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.
Financial terms were not disclosed.
Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.
Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。